newsfilter
← Latest News
PR Newswire·

IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year

ICCM
  • IceCure Medical reported a 45% year-over-year revenue increase to $1.8 million for the six months ended June 30, 2026, driven by growth in ProSense® system sales & disposable probes.
  • The company expanded its U.S. commercial footprint with approximately 70% growth in its active installed base following FDA clearance.
  • Gross profit rose to $548,000 for the period, compared to $349,000 in the same period of 2025.
  • The company strengthened its balance sheet with $8.5 million in gross proceeds from financings during the first half of 2026, ending with $12.0 million in cash & cash equivalents.
  • Research & development expenses increased to $4.3 million due to the initiation of the FDA-approved CHoICE study & foreign exchange fluctuations.
  • Sales & marketing expenses grew to $2.5 million to support expansion of the U.S. sales organization & international markets including Brazil.
  • General & administrative expenses rose to $2.4 million primarily due to foreign exchange fluctuations & higher share-based compensation.
  • Clinical leadership strengthened through inclusion in the ASBrS resource guide, peer-reviewed publications, NCCN petitions, & positive five-year kidney cancer results presented at ECIO 2026.
  • The company reported a net loss of $8.775 million for the six months ended June 30, 2026, compared to $6.952 million in the prior year period.
  • IceCure continues to advance its CHoICE study to generate additional clinical evidence & drive future reimbursement opportunities.